Professional Documents
Culture Documents
Field: Life Science Topic: The Challenges To Create Immediate Vaccine of COVID-19
Field: Life Science Topic: The Challenges To Create Immediate Vaccine of COVID-19
While running the tests, other challenges have to be faced considering the
aspects that influence the target of the test, such as ethic codes, values, and
necessity. Challenge studies create a high-risk situation for the participants and
people all over the world. To date, no medication is scientifically proven to be
effective for COVID-19 treatment. US and Japan were authorizing the emergency
usage for Remdesivir, then followed by other countries, its basic clinical proof
that underlies its effectivity is still limited and doesn’t show a significant mortal
rate decrease. Some experts said that challenge studies are not suitable for any
potentially fatal disease that lacks effective treatment. There’s also a clear age
effect, with a much lower mortality rate in a younger individual. In French,
individuals age 20-29 are predicted to have an infected fatality ratio of about
0.007%, which comparable to the annual risk of dying in a traffic accident.
COVID-19 challenge studies might be recruiting the younger volunteers to
minimize the risk of having harmful results. The results in these populations
might not be generalized for the older individual and they have the most profitable
comorbidity from the effective vaccine. This kind of approach can accelerate the
promising vaccine candidate development to the phase III trial in a high-risk
community. A tight observation with the severe side effects in the challenge
studies also increases a faster medication possibility. This will helps to decrease
the dangerous risk compared to community transmission, in which the lack of
relevant symptoms detection will lead to some delay in hospitalization.